Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company's lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy in Phase 2b clinical development for patients with generalized myasthenia gravis. Cartesian Therapeutics, formerly known as Selecta Biosciences Inc., is based in WATERTOWN, Mass.
| Revenue (Most Recent Fiscal Year) | $2.80M |
| Net Income (Most Recent Fiscal Year) | $-130.30M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 154.77 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -10906.16% |
| Net Margin (Trailing 12 Months) | -8550.65% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -29.84% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.48 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.48 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-4.14 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.46 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.84 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.94 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 30.25M |
| Free Float | 19.00M |
| Market Capitalization | $274.72M |
| Average Volume (Last 20 Days) | 0.11M |
| Beta (Past 60 Months) | 0.62 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 37.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.95% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |